Psychiatric Times articleshttps://www.psychiatrictimes.com/newsPsychiatric Times articles© 2026 MJH Life Sciences™ and Psychiatric Times. All rights reserved.Fri, 30 Oct 2026 11:17:49 +00005en-us14447https://www.psychiatrictimes.com/newshttps://www.psychiatrictimes.com/logo.webphttps://www.psychiatrictimes.com/view/hhs-updates-national-alzheimer-disease-plan-to-prioritize-preventionhttps://www.psychiatrictimes.com/view/hhs-updates-national-alzheimer-disease-plan-to-prioritize-prevention<![CDATA[HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.]]>Thu, 29 Oct 2026 18:47:31 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/neflamapimod-for-dementia-with-lewy-bodies-misses-end-point-subgroup-signal-emergeshttps://www.psychiatrictimes.com/view/neflamapimod-for-dementia-with-lewy-bodies-misses-end-point-subgroup-signal-emerges<![CDATA[Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.]]>Thu, 29 Oct 2026 18:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/assessing-interventions-for-insomnia-in-peri--and-postmenopausal-womenhttps://www.psychiatrictimes.com/view/assessing-interventions-for-insomnia-in-peri--and-postmenopausal-women<![CDATA[A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.]]>Thu, 29 Oct 2026 16:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/awareness-of-alcohol-use-disorder-medication-is-low-among-us-adults-study-findshttps://www.psychiatrictimes.com/view/awareness-of-alcohol-use-disorder-medication-is-low-among-us-adults-study-finds<![CDATA[National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.]]>Wed, 28 Oct 2026 18:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/food-noise-and-glp-1-drugs-what-research-reveals-about-motivation-and-appetitive-drivehttps://www.psychiatrictimes.com/view/food-noise-and-glp-1-drugs-what-research-reveals-about-motivation-and-appetitive-drive<![CDATA[GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.]]>Wed, 28 Oct 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/reading-body-language-in-mdd-a-story-that-changed-practicehttps://www.psychiatrictimes.com/view/reading-body-language-in-mdd-a-story-that-changed-practice<![CDATA[In-person visits let Erin Crown read incongruence between what a patient says and how they present, and one encounter years ago showed her exactly why that matters.]]>Wed, 28 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-lingering-blah-residual-symptoms-and-sleep-as-an-early-warning-signhttps://www.psychiatrictimes.com/view/the-lingering-blah-residual-symptoms-and-sleep-as-an-early-warning-sign<![CDATA[A vague sense of 'blah' is often the last symptom to lift. Dr. Harding and Dr. Citrome examine why anhedonia and disrupted sleep persist longest, and how tracking them closely reveals early warning signs.]]>Wed, 28 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/dementia-pipeline-update-phase-2-and-3-developments-in-alzheimer-disease-and-lewy-body-dementiahttps://www.psychiatrictimes.com/view/dementia-pipeline-update-phase-2-and-3-developments-in-alzheimer-disease-and-lewy-body-dementia<![CDATA[Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.]]>Tue, 27 Oct 2026 18:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/burnout-gratitude-and-the-value-of-staying-current-on-the-mind-of-gus-alva-md-dfapahttps://www.psychiatrictimes.com/view/burnout-gratitude-and-the-value-of-staying-current-on-the-mind-of-gus-alva-md-dfapa<![CDATA[Gus Alva, MD, DFAPA, joins Erin Crown to discuss how regional meetings, industry exchange, and emerging treatments can help clinicians avoid burnout and better serve patients.]]>Tue, 27 Oct 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-staying-engaged-in-psychiatry-beyond-the-lecture-hallhttps://www.psychiatrictimes.com/view/podcast-staying-engaged-in-psychiatry-beyond-the-lecture-hall<![CDATA[Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.]]>Tue, 27 Oct 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-economic-cost-of-undertreated-adult-adhdhttps://www.psychiatrictimes.com/view/the-economic-cost-of-undertreated-adult-adhd<![CDATA[Medication access and cost shape ADHD outcomes as much as the prescription itself. The panel examines shortages, pricing, and the real economic toll of inadequately treated ADHD.]]>Tue, 27 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/new-adhd-formulations-patches-and-patient-trusthttps://www.psychiatrictimes.com/view/new-adhd-formulations-patches-and-patient-trust<![CDATA[Patches, liquids, and a newly approved triple reuptake inhibitor are expanding the ADHD treatment toolkit. The panel discusses when to reach beyond familiar medications and how to build patient trust in doing so.]]>Tue, 27 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/daridorexant-orexin-receptor-agonist-shows-positive-results-in-pediatric-insomniahttps://www.psychiatrictimes.com/view/daridorexant-orexin-receptor-agonist-shows-positive-results-in-pediatric-insomnia<![CDATA[Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.]]>Mon, 26 Oct 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/synapse-level-mapping-could-reveal-how-disrupted-brain-circuits-lead-to-psychiatric-disordershttps://www.psychiatrictimes.com/view/synapse-level-mapping-could-reveal-how-disrupted-brain-circuits-lead-to-psychiatric-disorders<![CDATA[New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.]]>Mon, 26 Oct 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/revisiting-mdd-management-in-primary-carehttps://www.psychiatrictimes.com/view/revisiting-mdd-management-in-primary-care<![CDATA[Two decades after a landmark STAR*D trial recalibrated expectations, Dr. DeBattista argues the standard of care has barely moved, and that measurement-based care remains the underused lever.]]>Mon, 26 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/mdd-side-effect-profiles-counseling-adherence-and-suicidality-monitoringhttps://www.psychiatrictimes.com/view/mdd-side-effect-profiles-counseling-adherence-and-suicidality-monitoring<![CDATA[The side effect that stops the drug is usually the one nobody warned about. The panel works through what belongs in the first conversation and how often to reassess for suicidality.]]>Mon, 26 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/fda-aligns-on-key-elements-of-phase-3-study-of-zervimesine-for-dementia-with-lewy-bodieshttps://www.psychiatrictimes.com/view/fda-aligns-on-key-elements-of-phase-3-study-of-zervimesine-for-dementia-with-lewy-bodies<![CDATA[FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.]]>Fri, 23 Oct 2026 14:58:14 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/sleep-disruption-and-alzheimer-disease-a-bidirectional-treatable-relationshiphttps://www.psychiatrictimes.com/view/sleep-disruption-and-alzheimer-disease-a-bidirectional-treatable-relationship<![CDATA[Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.]]>Fri, 23 Oct 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/new-multi-arm-multi-stage-uk-trial-to-test-alzheimer-treatmentshttps://www.psychiatrictimes.com/view/new-multi-arm-multi-stage-uk-trial-to-test-alzheimer-treatments<![CDATA[UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.]]>Thu, 22 Oct 2026 13:27:28 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/when-antidepressants-stop-working-understanding-tachyphylaxis-in-clinical-practicehttps://www.psychiatrictimes.com/view/when-antidepressants-stop-working-understanding-tachyphylaxis-in-clinical-practice<![CDATA[When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.]]>Wed, 21 Oct 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/what-do-patient-level-studies-tell-us-about-antidepressants-and-suicide-riskhttps://www.psychiatrictimes.com/view/what-do-patient-level-studies-tell-us-about-antidepressants-and-suicide-risk<![CDATA[The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations. ]]>Wed, 21 Oct 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-diego-regalado-md-on-culturally-responsive-psychiatric-care-for-hispanic-patientshttps://www.psychiatrictimes.com/view/podcast-diego-regalado-md-on-culturally-responsive-psychiatric-care-for-hispanic-patients<![CDATA[A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.]]>Wed, 21 Oct 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/improving-but-not-feeling-it-anticipatory-anhedonia-and-cognitionhttps://www.psychiatrictimes.com/view/improving-but-not-feeling-it-anticipatory-anhedonia-and-cognition<![CDATA[A patient's improving score does not always translate into a patient who feels better, and Erin Crown explains how anhedonia and cognitive symptoms account for the gap.]]>Wed, 21 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/who-defines-success-realistic-goals-and-hidden-nonadherencehttps://www.psychiatrictimes.com/view/who-defines-success-realistic-goals-and-hidden-nonadherence<![CDATA[More than half of patients treated for depression don't believe full remission is achievable. The panel explores what success should mean to the patient in front of you, and why patients rarely admit they've stopped taking a medication.]]>Wed, 21 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/positive-topline-results-from-phase-2-trial-of-rap-219-for-the-treatment-of-bipolar-maniahttps://www.psychiatrictimes.com/view/positive-topline-results-from-phase-2-trial-of-rap-219-for-the-treatment-of-bipolar-mania<![CDATA[Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.]]>Tue, 20 Oct 2026 16:02:20 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/evidence-based-ethical-principles-for-long-acting-injectable-antipsychotic-usehttps://www.psychiatrictimes.com/view/evidence-based-ethical-principles-for-long-acting-injectable-antipsychotic-use<![CDATA[Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.]]>Tue, 20 Oct 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/phase-2-clinical-study-initiated-evaluating-nbi--567-for-the-treatment-of-adults-with-alzheimer-diseasehttps://www.psychiatrictimes.com/view/phase-2-clinical-study-initiated-evaluating-nbi--567-for-the-treatment-of-adults-with-alzheimer-disease<![CDATA[Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.]]>Tue, 20 Oct 2026 13:04:16 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/practical-takeaways-advancing-schizophrenia-care-through-educationhttps://www.psychiatrictimes.com/view/practical-takeaways-advancing-schizophrenia-care-through-education<![CDATA[Closing the discussion, the panel offers practical guidance on patient education, ongoing clinical learning, and community-based research opportunities to help clinicians move schizophrenia care forward.]]>Tue, 20 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/inside-the-technology-behind-extended-release-adhd-medicationshttps://www.psychiatrictimes.com/view/inside-the-technology-behind-extended-release-adhd-medications<![CDATA[Behind every extended-release stimulant is an engineering problem: how to release medication predictably over hours. The panel breaks down the microparticle and polymer technologies making that possible.]]>Tue, 20 Oct 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/supporting-caregivers-and-families-through-schizophrenia-treatmenthttps://www.psychiatrictimes.com/view/supporting-caregivers-and-families-through-schizophrenia-treatment<![CDATA[Caregivers carry an enormous, often invisible burden in schizophrenia care. The panel discusses how curiosity, communication, and community resources can support families while helping patients hold onto hope.]]>Tue, 20 Oct 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articles